# Study of TRC102 in Combination With Pemetrexed in Cancer Patients

> **NCT00692159** · PHASE1 · COMPLETED · sponsor: **Tracon Pharmaceuticals Inc.** · enrollment: 28 (actual)

## Conditions studied

- Neoplasm

## Interventions

- **DRUG:** TRC102 + pemetrexed

## Key facts

- **NCT ID:** NCT00692159
- **Lead sponsor:** Tracon Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2010-06
- **Final completion:** 2010-09
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2010-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00692159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00692159, "Study of TRC102 in Combination With Pemetrexed in Cancer Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00692159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*